Cartesian Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 29 →Insiders1 insider bought $205,800 in 1 open-market buy. 3 insiders sold $258,683, 0 of 3 sales on a 10b5-1 plan.→HoldersSquarepoint Ops 7.5%BlackRock 2.7%683 2.2%→Financing →PeersClosest companies: CRVS, XNCR, XLO→
From the filings
Figures
- Revenue
- $1.5Mlast 12 months
- Net income
- −$151.9Mlast 12 months
- Operating cash flow
- −$73.0Mlast 12 months
- Cash and equivalents
- $147.6Mat the last balance sheet
- Total debt
- $52.9Mat the last balance sheet
- Shares outstanding
- 30.0M shareson issue